Speakers
Attendees
Sessions
The next big question in cancer immunotherapy is what’s next in immuneoncology?
Overcoming resistance to various combinatorial approaches, selecting the patients and developing translational hypothesis besides designing optimal preclinical models for immunological agents, different strategies to regulate the microbiome are some of the major challenges faced by cancer research experts in the US.
Following the success of our UK Edition, MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress-US Edition to be held on 21st and 22nd June 2018 in Philadelphia, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiomederived immunotherapy and new paradigms in immune checkpoint inhibitors
This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.
Register for our 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress 2020, write an email to [email protected]
Senior Vice President, Global Medical Affairs, Celgene
Executive Vice President, Chief Medical Officer, Eikon Therapeutics
Executive Director, Research, Amgen
Founder and Chief Scientist, BioIncept LLC
Professor and Chair, Department of Biomedical Sciences, University of Pennsylvania
Director, Translational Science and Bioanalytical, Vaccinex
Senior Application Scientist, Insphero
Senior Manager, Applications for Immunooncology and Vaccines , JSR Micro Life Sciences and MBL International
Senior Director, Caris Lifesciences
Head, Cellular Immunology, NIH
Chief Scientific Officer, Oncorus
CEO, Cure Pharmaceuticals
CEO, OmniSeq
Director, GMP for Immunotherapy, Assistant Professor, Children’s National Medical Centre
CEO, Ossianix Inc.
Immuno-Oncology Lead, Takeda Oncology
Head, Tumor Immunotherapy, Seres Therapeutics
Global Subject Matter Expert, Lonza Pharma Bioscience Solutions
Associate Director, Translational Applications, Mitra Biotech
Director, Pharmacology, ncyte
Senior Scientist, Head, Immuno-Oncology, Medgenome
Director of Cancer Center, The University of Connecticut School of Medicine
Executive Vice President, Chief Medical Officer, Eikon Therapeutics
Executive Director, Research, Amgen
Vice President, Clinical Development Immuno- Oncology, Inovio
Senior Vice President, CSO, MacroGenics
Professor, Center for Cancer Immunotherapy, La Jolla University
CEO, Gritstone Oncology
Senior Research Scientist, The Jackson Laboratory
CEO, Bionavigen
Senior Vice President, Global Medical Affairs, Celgene
Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania
Senior Director Vaccine Research, Agenus
Vice President, Clinical Development, Nektar Therapeutics
Scientific Project Manager, Nebion
Director, Translational Medicine, Genocea
Senior Director, Clinical Development, Kite Pharma
Associate Member, Attending Physician, Memorial Sloan Kettering Cancer Centre
Vice President, Business Development, ACD-Bio-Biotechne
Philadelphia - USA
